Literature DB >> 7672955

Migraine symptoms: results of a survey of self-reported migraineurs.

S D Silberstein1.   

Abstract

Migraine is an episodic headache disorder associated with various combinations of neurologic, gastrointestinal, and autonomic symptoms. Gastrointestinal disturbances including nausea, vomiting, abdominal cramps, or diarrhea are almost universal. Sensory hyperexcitability manifested by photophobia, phonophobia, and osmophobia are frequently experienced. Other symptoms include blurry vision, nasal stuffiness, tenesmus, polyuria, pallor, and sweating. Our telephone interview survey of 500 self-reported migraine sufferers was performed in 1994. The most common reported symptoms associated with migraine were pain, nausea, problems with vision, and vomiting. Nausea occurred in more than 90% of all migraineurs; nearly one third of these experienced nausea during every attack. Vomiting occurred in almost 70% of all migraineurs; nearly one third of these vomited in the majority of attacks. In those who experienced nausea, 30.5% indicated that it interfered with their ability to take their oral migraine medication; in those with vomiting, 42.2% indicated that it interfered with their ability to take their oral migraine medication. The most important features of a migraine medication were rapid and effective relief of headache pain, decreasing the likelihood of headache recurrence, and not causing nausea. Many migraine patients suffer needlessly because their nausea and vomiting are both unreported to, and unrecognized by physicians. The presence of these symptoms is crucial to diagnose migraine not accompanied by aura.

Entities:  

Mesh:

Year:  1995        PMID: 7672955     DOI: 10.1111/j.1526-4610.1995.hed3507387.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  42 in total

Review 1.  Migraine: multiple processes, complex pathophysiology.

Authors:  Rami Burstein; Rodrigo Noseda; David Borsook
Journal:  J Neurosci       Date:  2015-04-29       Impact factor: 6.167

Review 2.  Transdermal delivery of sumatriptan for the treatment of acute migraine.

Authors:  Mark W Pierce
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 3.  Assessing the efficacy of drugs for the acute treatment of migraine: issues in clinical trial design.

Authors:  Nabih M Ramadan
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 4.  Needle-free subcutaneous sumatriptan: in the acute treatment of migraine attacks or cluster headache episodes.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

5.  Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.

Authors:  David W Dodick; Giorgio Sandrini; Paul Williams
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

6.  Fixed-dose Sumatriptan/Naproxen Sodium Compared with each Monotherapy Utilizing the Novel Composite Endpoint of Sustained Pain-free/no Adverse Events.

Authors:  Stephen Landy; Jonathan White; Shelly E Lener; Susan A McDonald
Journal:  Ther Adv Neurol Disord       Date:  2009-05       Impact factor: 6.570

Review 7.  The iontophoretic transdermal system formulation of sumatriptan as a new option in the acute treatment of migraine: a perspective.

Authors:  Michail Vikelis; Konstantinos C Spingos; Alan M Rapoport
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

8.  Mapping migraine to a common brain network.

Authors:  Matthew J Burke; Juho Joutsa; Alexander L Cohen; Louis Soussand; Danielle Cooke; Rami Burstein; Michael D Fox
Journal:  Brain       Date:  2020-02-01       Impact factor: 13.501

9.  Interictal quantitative EEG in migraine: a blinded controlled study.

Authors:  Marte Helene Bjørk; Lars J Stovner; Morten Engstrøm; Marit Stjern; Knut Hagen; Trond Sand
Journal:  J Headache Pain       Date:  2009-08-25       Impact factor: 7.277

Review 10.  Rizatriptan: an update of its use in the management of migraine.

Authors:  Keri Wellington; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.